Mucosal DTPa vaccines
View Patent ↗Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a mucosal adjuvant. The acellular pertussis antigen preferably comprises pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) and, optionally, pertactin. The mucosally-delivered combined DTPa formulation is capable of generating a level of protection against B. pertussis infection equivalent to that observed by alum-adjuvanted parenteral administration.
1. An intranasal vaccine comprising:
a diphtheria toxoid, a tetanus toxoid, and an acellular pertussis antigen (DTPa) comprising detoxified pertussis holotoxin; and
a detoxified E. coli heat labile toxin, wherein the detoxified E. coli heat labile toxin is LT-K63 or LT-R72.
2. The intranasal vaccine of claim 1 , wherein the acellular pertussis antigen comprises filamentous haemagglutinin.
3. The intranasal vaccine of claim 2 , wherein the acellular pertussis antigen further comprises pertactin.
4. The intranasal vaccine of claim 2 , wherein the detoxified pertussis holotoxin is 9K/129G double mutant.
5. The intranasal vaccine of claim 1 , wherein the diphtheria toxoid is CRM197.
6. The intranasal vaccine of claim 1 further comprising at least one additional non-DTP antigen which does not diminish the immune response against said DTPa.
7. A method of generating an immune response against diphtheria, tetanus, and whooping cough in a patient comprising intranasally administering to the patient the vaccine of claim 1 .
8. The method of claim 7 , wherein the patient is a child.
9. The method of claim 7 , wherein the intranasal administration is performed at least twice.